NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Q32 Bio Inc. (QTTB) Stock Analysis

Q32 Bio Inc. (QTTB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

QTTB

$8.67

+$0.05 (+0.58%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QTTB with… →

QTTB Key Statistics

As of Oct 21, 2026
Trading
Open
$8.62
Previous Close
$8.62
Day's Range
8.56–8.81
52-Week Range
1.91–23.57
Volume
321.83K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.11
Valuation
Market Cap
$258.10M
P/E Ratio
2.75
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.80
EPS (ttm)Profit attributable to each share over the last twelve months.
3.15
Financials (FY)
Revenue (FY)
$53.74M
Net Income (FY)
$29.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
62.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.77M
1-Year Return
+191.92%
Dividend and dates
Avg Volume
720.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, QTTB closed at $8.67, +191.92% over 1 year.

Q32 Bio Inc. (QTTB) has a market capitalization of $258.10M.

In fiscal 2025, QTTB reported revenue of $53.74M.

QTTB Stock Return by Calendar Year

Q32 Bio Inc. (QTTB) return since Mar 2018: what $10,000 became

1 year
$10,000 $29,192
+191.92%
5 years
$10,000 $792
−92.08%
Since Mar 2018
$10,000 $258
−97.42%

If you had invested $10,000 in Q32 Bio Inc. (QTTB) at the close on March 28, 2018, the earliest close on record here, it would have been worth $258 at the close on October 21, 2026: −97.42% in total, −34.75% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+161.14%
2025−3.49%
2024−68.57%
2023−51.75%
2022−65.38%
2021−67.76%
2020−45.46%
2019−7.42%
2018 (partial year)+19.83%

As of October 21, 2026.

QTTB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$53.74M$29.82M55.5%
2024$0.00−$47.73M—
2023−$6.65M−$53.74M808.0%
2022$6.65M−$42.81M−643.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$53.74M—$16.90M$29.82M55.5%
2024$0.00—−$66.10M−$47.73M—
2023−$6.65M—−$48.26M−$53.74M808.0%
2022$6.65M—−$39.23M−$42.81M−643.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QTTB Valuation vs Biotechnology Median

Median of 608 stocks
MetricQTTBBiotechnology medianvs median
P/E2.7516.600.2x the median
P/S ratio4.8013.3064% below
Profit margin62.87%−38.31%101.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Q32 Bio Inc. (QTTB) carries a market capitalisation of $258.10M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 22.

Over the past 52 weeks the price has ranged from $1.91 to $23.57. QTTB last closed at $8.67 on October 21, 2026. That is +$0.05 (+0.58%) against the previous close. The latest close sits 355.12% above that 52-week low.

Financial Health

In fiscal 2025, Q32 Bio Inc. reported revenue of $53.74M. The same year closed with net income of $29.82M. The reported profit margin is 62.87%. That is 101.2 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 3.15.

Across the 4 fiscal years on file, revenue moves from $6.65M in 2022 to $53.74M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 2.75. That is 0.2 times the Biotechnology median of 16.6. The price-to-sales ratio is 4.8. On price-to-sales that is 63.88% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at −0.11. Daily returns over the trailing 8 years annualize to a volatility of 112.16%. The trailing one-year total return is +191.92%. Measured over 5 years, that is −39.78% a year compounded.

Growth & Income

No dividend is on file for QTTB.

So far in 2026 the total return is +161.14%. Across the complete calendar years on file, 2025 returned −3.49% and 2024 returned −68.57%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Q32 Bio Inc. (QTTB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Q32 Bio Inc. QTTB $258.10M 2.8
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Q32 Bio Inc. trades at a P/E of 2.8.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Q32 Bio Inc.

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Visit website →